Welcome to our dedicated page for Green Planet Bioengineering Co SEC filings (Ticker: GPLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Green Planet Bioengineering Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Green Planet Bioengineering Co's regulatory disclosures and financial reporting.
Green Planet Bioengineering Co., Ltd. (GPLB) is a public reorganized shell corporation with no active operations or revenue for the years ended December 31, 2025 and 2024. It exists primarily to acquire or merge with an operating business.
For 2025, the company recorded administrative expenses of $35,842, resulting in a net loss of the same amount, similar to the $35,544 loss in 2024. As of December 31, 2025, it reported no assets or cash, current liabilities of $500,976, and an accumulated deficit of $1,130,596.
Funding needs were met entirely by a related party, Global Funds Holdings Corp., which advanced $484,678 on an interest-free, unsecured, on-demand basis. Auditors issued going concern language, citing dependence on this related party and the lack of operations. A single stockholder, Global Funds, beneficially owns about 92% of the 20,006,402 common shares outstanding.
Green Planet Bioengineering (GPLB) filed its Q3 2025 report, remaining a public shell with no active operations and disclosing substantial doubt about its ability to continue as a going concern.
For the quarter ended September 30, 2025, the company recorded a net loss of $8,599, bringing the nine‑month net loss to $19,544, driven by administrative costs. As of September 30, 2025, it reported zero cash, a working capital deficit of $484,678, and an accumulated deficit of $1,114,298. Current liabilities include $479,148 due to a related party, which is interest‑free, unsecured, and payable on demand. A subsequent event notes an additional $5,530 advanced by the related party after October 1, 2025.
Common shares outstanding were 20,006,402 as of November 14, 2025. Management states disclosure controls and procedures were effective. The company continues to rely on related‑party funding while it seeks potential business combinations.